1
|
Kotsifaki A, Alevizopoulos N, Dimopoulou V, Armakolas A. Unveiling the Immune Microenvironment's Role in Breast Cancer: A Glimpse into Promising Frontiers. Int J Mol Sci 2023; 24:15332. [PMID: 37895012 PMCID: PMC10607694 DOI: 10.3390/ijms242015332] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2023] [Revised: 10/13/2023] [Accepted: 10/16/2023] [Indexed: 10/29/2023] Open
Abstract
Breast cancer (BC), one of the most widespread and devastating diseases affecting women worldwide, presents a significant public health challenge. This review explores the emerging frontiers of research focused on deciphering the intricate interplay between BC cells and the immune microenvironment. Understanding the role of the immune system in BC is critical as it holds promise for novel therapeutic approaches and precision medicine strategies. This review delves into the current literature regarding the immune microenvironment's contribution to BC initiation, progression, and metastasis. It examines the complex mechanisms by which BC cells interact with various immune cell populations, including tumor-infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs). Furthermore, this review highlights the impact of immune-related factors, such as cytokines and immune checkpoint molecules. Additionally, this comprehensive analysis sheds light on the potential biomarkers associated with the immune response in BC, enabling early diagnosis and prognostic assessment. The therapeutic implications of targeting the immune microenvironment are also explored, encompassing immunotherapeutic strategies and combination therapies to enhance treatment efficacy. The significance of this review lies in its potential to pave the way for novel therapeutic interventions, providing clinicians and researchers with essential knowledge to design targeted and personalized treatment regimens for BC patients.
Collapse
Affiliation(s)
| | | | | | - Athanasios Armakolas
- Physiology Laboratory, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece; (A.K.); (N.A.); (V.D.)
| |
Collapse
|
2
|
Alexandris D, Alevizopoulos N, Marinos L, Kanellis G, Gakiopoulou C. Lichenoid drug eruption associated with imatinib mesylate therapy. J Oncol Pharm Pract 2023; 29:252-257. [PMID: 35473395 DOI: 10.1177/10781552221096846] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
INTRODUCTION Imatinib Mesylate (IM), a tyrosine kinase inhibitor, has been reported to cause several adverse reactions, most of them with cutaneous involvement. Non- Lichenoid IM associated skin reactions have been sufficiently- recorded. To our knowledge, Lichenoid Drug Eruption (LDE) is recorded in a minority of registries. CASE REPORT To describe an LDE induced case by IM treatment. TREATMENT AND OUTCOME Histological Confirmation and promptly dermatological consultation relieved successfully the cutaneous adverse event. DISCUSSION Ongoing expansion of IM usage in a wide spectrum of new indications is more likely to make physicians experience such LDE cutaneous side effects more often. Hence, they should be highly suspicious to early detect these distinct histologic entities, handle these undesired complications and guarantee satisfactory immediate outcomes, avoiding frivolous IM dosage modifications.
Collapse
Affiliation(s)
| | | | - Leonidas Marinos
- Department of Oncology, 69032Evaggelismos Hospital, Athens, Greece
| | | | - Charikleia Gakiopoulou
- First Department of Pathology, 68989Medical School of University of Athens, Athens, Greece
| |
Collapse
|
3
|
Alevizopoulos N, Alexandris D, Oreopoulos V, Palamaris K, Gakiopoulou C, Theocharis S, Vaslamatzis M. Small Cell Carcinoma (SmCC) of the bladder, treated in one Athenian oncologic center. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)02593-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
4
|
Alexandris D, Alevizopoulos N, Palamaris K, Gakiopoulou C, Theocharis S. Pinnae and facial hypertrichosis induced by cetuximab. J Oncol Pharm Pract 2022; 29:731-737. [PMID: 35821579 DOI: 10.1177/10781552221114073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
INTRODUCTION Anti-EGFR targeted anti-cancer treatment is associated with various skin adverse events. Cetuximab is often associated with acneiform papules and skin disorders. Hypertrichosis cited in face pinnae and eyelash trichomegaly are seldom described. CASE REPORT A 72-year-old female cancer patient presented deteriorating facial-pinnae hypertrichosis and eyelash prolongation post cetuximab infusion. MANAGEMENT AND OUTCOME Consecutive cetuximab administration led to exaggerating hairy skin side effects, fully alleviated when the drug was discontinued. DISCUSSION To the best of our knowledge, this is the first reported case of an anti-EGFR-associated diffuse pinnae hypertrichosis presentation in a female patient in literature. This distinct entity can be easily diagnosed and manipulated with early drug withdrawal. An extensive review of relevant basic molecular research is provided to increase physicians' awareness.
Collapse
Affiliation(s)
| | | | - Kostas Palamaris
- First Department of Pathology, 68989Medical School of University of Athens, Athens, Attica, Greece
| | - Charikleia Gakiopoulou
- First Department of Pathology, 68989Medical School of University of Athens, Athens, Attica, Greece
| | - Stamatios Theocharis
- First Department of Pathology, 68989Medical School of University of Athens, Athens, Attica, Greece
| |
Collapse
|
5
|
Alexandris D, Alevizopoulos N, Gakiopoulou H, Stavrinou N, Vourlakou C. Cutaneous Stevens Johnson - Toxic Epidermal Necrolysis Immunotherapy related Toxicities in Lung Cancer Patients. J Oncol Pharm Pract 2022:10781552221074623. [PMID: 35038934 DOI: 10.1177/10781552221074623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
INTRODUCTION New Immuno- Checkpoint inhibitors (ICIs) functioning as PD-1- PDL-1 blockers are nowadays used in a majority of anticancer treatments. Many immune- related Adverse Events (irAEs) are published daily; severe skin toxicities, Stevens Johnson/ Toxic Epidermal Necrolysis (SJS/TEN) are seldom reported. CASE REPORT Herein, we present two interesting skin sever toxicity cases of lung cancer patients, undergoing PD-1- PDL-1 Immunotherapy. In both cases, a morbilliform rash with documented histological Toxic Epidermal Necrolysis Pattern /Stevens Johnson findings, was thoroughly studied. MANAGEMENT & OUTCOME Both cases were therapeutically managed according to guidelines with different outcome. DISCUSSION Two focused cases of irAEs, is the rationale, to briefly review mechanisms of major toxicities caused by PD-1/PD-L1 blockade, and present all new data in their precise management. ICIs' association with SJS/ TEN still remains unclear; underlying urgent need for further studies. It is important to alert physicians to promptly identify life threatening irAEs. Being familiar, provides management efficacy, safe resolve and encourage beneficial balanced cost effective treatments.
Collapse
Affiliation(s)
| | | | - Harikleia Gakiopoulou
- First Department of Pathology, National and Kapodistrian University of Athens, Athens, Greece
| | - Nikolina Stavrinou
- Department of Pathology, 69032Evaggelismos General Hospital, Athens, Greece
| | | |
Collapse
|
6
|
Kyriazidou E, Alevizopoulos N, Dokutsidou E, Kavga A, Kalemikerakis I, Konstantinidis T, Tsatsou I, Govina O. Health-Related Quality of Life and Social Support of Elderly Lung and Gastrointestinal Cancer Patients Undergoing Chemotherapy. SAGE Open Nurs 2022; 8:23779608221106444. [PMID: 35720207 PMCID: PMC9201296 DOI: 10.1177/23779608221106444] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2022] [Accepted: 05/22/2022] [Indexed: 11/17/2022] Open
Abstract
Introduction Increasing life expectancy has led to a higher incidence of cancer in the elderly, thus making them vulnerable and worsening their health-related quality of life (HRQoL) and their need for support. Objective The aim of this study was to examine the HRQoL and social support in elderly Greek lung and gastrointestinal cancer patients undergoing chemotherapy. Methods This was a descriptive, cross-sectional study of 104 elderly cancer patients, who were receiving chemotherapy in the outpatient department and inpatient ward of a General Hospital in Athens. The data were collected using purposive sampling between December 2019 and May 2020, and included demographic and clinical characteristics, the HRQoL questionnaire, Short Form 36 (SF36), and the Personal Resource Questionnaire (PRQ-2000). Results The participants' median age was 72 years; the majority were male (62.5%) and had lung cancer (57.7%). The SF36 data revealed a relatively moderate (42.7-62.61) HRQoL in most subscales. The "Pain" subscale recorded the highest score (75.0), and the "social function" subscale the lowest (42.79). The PQR-2000 indicated a satisfactory level of social support (81.65), with values ranging between 48 and 105; married patients with higher education scored more highly (p < .05). Patients aged 65-75 years reported better HRQoL and greater social support than older patients. In addition, patients with their own family and a relatively high income reported better HRQoL and social support compared to single individuals, with low income, who were cared for by their children. Positive and statistically significant (p < .05) correlations were found between the SF36 subscales of role functioning/physical, vitality, general health, emotional well-being and the PRQ-2000. Conclusion The HRQoL and social support of elderly cancer patients positively affect the course of their health. Healthcare systems and social services should address the multiplying needs of these patients with targeted interventions to support their well-being.
Collapse
Affiliation(s)
- Eleni Kyriazidou
- Oncology Department, "Evangelismos" General Hospital of Athens, Athens, Greece
| | | | - Eleni Dokutsidou
- Department of Nursing, University of West Attica, Athens, Greece
| | - Anna Kavga
- Department of Nursing, University of West Attica, Athens, Greece
| | | | | | - Ioanna Tsatsou
- Oncology-Hematology Department, Hellenic Airforce General Hospital, Athens, Greece
| | - Ourania Govina
- Department of Nursing, University of West Attica, Athens, Greece
| |
Collapse
|
7
|
Alevizopoulos N, Alexandris D, Folinas K, Dimitriadou A, Pavlakis M, Kammenou H. EFFICACY AND SAFETY PROFILE OF PALBOCICLIB AND FULVESTRANT IN PATIENTS ER+/HER2– METASTATIC BREAST CANCER OF A SINGLE ONCOLOGICAL CENTRE. Breast 2021. [DOI: 10.1016/s0960-9776(21)00582-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
8
|
Fourtziala E, Givalos N, Alexakis N, Griniatsos J, Alevizopoulos N, Kavantzas N, C Lazaris A, Korkolopoulou P, Gakiopoulou H. Replication Protein A (RPA1, RPA2 and RPA3) expression in gastric cancer: correlation with clinicopathologic parameters and patients' survival. J BUON 2020; 25:1482-1489. [PMID: 32862594] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
PURPOSE Replication Protein A (RPA) consists of three subunits (RPA1, RPA2 and RPA3) essential for all major DNA metabolic pathways. Although RPA seems to be a promising therapeutic target, its role in human cancers has not been fully elucidated. This is the first study investigating the expression of all the three RPA subunits in a series of 74 resected gastric carcinomas and analyzing the possible correlations with clinicopathologic parameters (histological type, grade, lymphovascular invasion, lymph node status and disease stage), Ki-67 proliferative index, Topoisomerase IIa expression and patients' survival. METHODS Immunohistochemistry using monoclonal antibodies. Univariate and multivariate statistical analysis. RESULTS All the three subunits showed widespread nuclear expressions in gastric carcinomas with significant associations among their expressions. RPA2 demonstrated higher expression levels in low grade carcinomas and a gradual significant decrease from N0 to N3 and from stage I to stage IV carcinomas. All the three subunits were statistical significantly more abundant in lymph node negative and earlier stage (stage I & II) gastric carcinomas. No associations were established among RPAs and the proliferative marker Ki-67. In patients with positive lymph nodes and advanced tumor stage, RPA1 expression seemed to predict a better overall survival implying a probable predictive role. CONCLUSIONS The widespread expression of RPA(1-3) suggests one or more roles in gastric cancer. Their presence in earlier stage tumors probably offers an opportunity for early targeted therapy. Their probable predictive value in node positive and advanced stage tumors needs further investigation with respect to specific chemotherapeutic treatments.
Collapse
Affiliation(s)
- Efi Fourtziala
- 1st Department of Pathology, School of Medicine, The National and Kapodistrian University of Athens, Greece
| | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Sigala I, Alevizopoulos N, Elefteriou K, Gianniou N, Kalomenidis I. Primary squamous cell carcinoma of the pleura treated with nivolumab. Respirol Case Rep 2020; 8:e00516. [PMID: 32042427 PMCID: PMC7001115 DOI: 10.1002/rcr2.516] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2019] [Revised: 12/08/2019] [Accepted: 12/10/2019] [Indexed: 12/17/2022] Open
Abstract
Malignant pleural effusions usually manifest in the course of metastatic cancer disease. Primary pleural tumours are rare with mesothelioma being by far the most common. Primary squamous cell carcinoma of the pleura (PSCCP) is extremely rare. It is usually asymptomatic, until it invades the pleura presenting pain as the first symptom. Our knowledge about its treatment or prognosis is limited due to its rarity. We present the case of a 48-year-old man who presented with persistent right-sided thoracic pain with chest computed tomography (CT) scan demonstrating a right-sided pleural effusion and pleural mass invading the ribs. Ultrasound-guided biopsy revealed a PSCCP. Positron emission tomography staging demonstrated metastatic lung and lymph node involvement precluding surgical therapy. We provide information about treatment, including immunotherapy as well as extended follow-up course. Immunotherapy with nivolumab resulted in prolongation of survival with good quality of life.
Collapse
Affiliation(s)
- Ioanna Sigala
- 1st Department of Critical Care and Pulmonary MedicineEvaggelismos Hospital, National and Kapodistrian University of AthensAthensGreece
| | | | - Konstantinos Elefteriou
- 1st Department of Critical Care and Pulmonary MedicineEvaggelismos Hospital, National and Kapodistrian University of AthensAthensGreece
| | - Niki Gianniou
- 1st Department of Critical Care and Pulmonary MedicineEvaggelismos Hospital, National and Kapodistrian University of AthensAthensGreece
| | - Ioannis Kalomenidis
- 1st Department of Critical Care and Pulmonary MedicineEvaggelismos Hospital, National and Kapodistrian University of AthensAthensGreece
| |
Collapse
|
10
|
Alevizopoulos N, Dimitriadou A, Tegos T, Folinas K, Pavlakis M, Gioti A, Nikolaidou V, Vaslamatzis M. BONE MARROW BREAST CARCINOSIS: PATHOLOGICAL, CLINICAL PARAMETERS AND OUTCOME. A SINGLE INSTITUTION’S EXPERIENCE. Breast 2019. [DOI: 10.1016/s0960-9776(19)30729-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
11
|
Alevizopoulos N, Folinas K, Dimitriadou A, Gioti A, Tegos T, Pavlakis M, Vaslamatzis M. METASTATIC TRIPLE NEGATIVE BREAST CANCER TO RIGHT COLON; AN UNUSUAL FIRST PRESENTATION: A CASE REPORT AND LITERATURE REVIEW. Breast 2019. [DOI: 10.1016/s0960-9776(19)30752-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
12
|
Vaslamatzis M, Alevizopoulos N, Tegos T, Pavlakis M, Karagiorgou K, Zoumblios C, Gioti K, Nikolaidou V, Kyriazidou H, Balis E, Athanasiadou K. P2.01-61 Multiple Primary Carcinomas (MPC) in Patients with Non Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1404] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
13
|
Vaslamatzis M, Tegos T, Alevizopoulos N, Pavlakis M, Karagiorgou K, Patila E, Gioti K, Exarchos D, Zisis C. EP1.12-14 Multiple Primary Malignant Neoplasms in Patients with Small Cell Lung Cancer. The Experience of Our Center. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.2259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
14
|
Alevizopoulos N, Tegos T, Gioti A, Pavlakis M, Vaslamatzis M. Cardiovascular complications of elderly breast cancer patients. The experience of a single Oncology Institute. Breast 2019. [DOI: 10.1016/s0960-9776(19)30463-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
15
|
Alevizopoulos N, Pavlakis M, Tegos T, Gioti A, Dimitriadou A, Vaslamatzis M. Appearance of ductal breast carcinoma with gastrointestinal stromal tumor (GIST) in a female patient: an interesting coexistence. Breast 2019. [DOI: 10.1016/s0960-9776(19)30222-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
16
|
Vaslamatzis M, Laskarakis A, Tegos T, Pavlakis M, Argyrakos T, Alevizopoulos N, Zoublios C, Vasili E, Gioti E, Athanasiadi K. 177P Clinicopathologic characteristics in large cell neuroendocrine carcinomas of the lung (LCNCL): The experience of one center. J Thorac Oncol 2018. [DOI: 10.1016/s1556-0864(18)30451-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
17
|
Alevizopoulos N, Sigala I, Dimitriadou A, Tegos T, Edwin V, Ntalapera V, Loukas N, Vaslamatzis M. P2.04-043 Squamous Cell Carcinoma Arising from the Pleura. An Interesting Case Report. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2016.11.1423] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
18
|
Alevizopoulos N, Ntalapera V, Dimitriadou A, Skoula A, Vagdatlis T, Pissaki K, Loukas N, Vaslamatzis M. P1.03-031 Gynecological Malignancies and Imaging Patterns. An Interesting Case Report and Literature Surveillance. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2016.11.702] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
19
|
Alevizopoulos N, Sigala I, Tegos T, Dimitriadou A, Vagdatlis T, Skoula A, Ntalapera V, Loukas N, Vaslamatzis M. P2.04-042 Epithelial-Myoepithelial Tumor of Unknown Origin: An Interesting Case Report with Unexpected Outcome. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2016.11.1422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
20
|
Vaslamatzis M, Patila E, Tegos T, Alevizopoulos N, Zoumblios C, Kapou T, Stathopoulos C, Laskarakis A, Zisis C, Vasili E. P1.06-029 Epidemiologic, Clinical Characteristics and Therapeutic Strategy of Elderly NSCLC Patients Treated in a Single Institution. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2016.11.893] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
21
|
Liapis K, Kastritis E, Bagratouni T, Vassiliou S, Papachristidis A, Charitaki E, Alevizopoulos N, Harhalakis N, Terpos E, Delimpasi S, Dimopoulos MA. Early tumor-cell gene expression changes may predict the response to first-line bortezomib-based therapy in patients with newly diagnosed multiple myeloma. J BUON 2015; 20:1314-1321. [PMID: 26537080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
PURPOSE Maximizing the response rate to first-line therapy in patients with multiple myeloma (MM) is important because it leads to improved outcome. Gene-expression studies have identified prognostic gene sets in patients receiving bortezomib-based therapy. Comparison of the lists of genes derived from two gene-expression-based models (GEP70, GEP80) showed that they overlap in three genes, namely PSMD4, BIRC5, and KIAA1754. An unanswered question is whether early gene-expression changes can be used as predictors of the response to first-line bortezomib. In this study we aimed to examine the predictive value of gene expression changes for the depth of response after bortezomib-based therapy in newly diagnosed MM. METHODS We prospectively assessed the relation between early PSMD4, BIRC5, and KIAA1754 gene expression changes (before therapy and one week later) and the response rate after bortezomib-based therapy in 25 patients with newly diagnosed MM. Gene expression was studied by RT-PCR on CD138-selected plasma cells, and changes were recorded as upregulation, downregulation, or unchanged. RESULTS Whereas baseline prognostic factors including genetic lesions and stage were not predictive of the response rate, we found that early BIRC5 and KIAA1754 gene-expression changes were significantly associated with the depth of response to bortezomib (p=0.001 and p<0.001, respectively). PSMD4 was not predictive of the depth of response. KIAA1754 upregulation was linked to complete remission (CR) or very good partial remission (VGPR). BIRC5 upregulation was linked to stable disease (SD) or progressive disease (PD). We also observed that BIRC5 upregulation was associated with worse progression-free survival (PFS). CONCLUSIONS Our results suggest that BIRC5 and KIAA1754 gene-expression changes may predict the response to bortezomib-based therapy. These data may have relevance for the stratification and early adaptation of first-line treatment in patients with newly diagnosed MM.
Collapse
Affiliation(s)
- Konstantinos Liapis
- Haemato-Oncology Unit, The Royal Marsden Hospital, The Royal Marsden NHS Foundation Trust, Surrey, London, UK
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Vaslamatzis M, Patila E, Margari CP, Tegos TK, Alevizopoulos N, Kyriakopoylos G, Kyriou L, Laskarakis A, Kapou T, Stathopoulos C. The serum tumour marker Ca19-9 in non-small cell lung cancer (NSCLC). J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.e18535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Elisabeth Patila
- Department of Oncology Evaggelismos General Hospital, Athens, Greece
| | | | | | | | | | - Lamprini Kyriou
- Department of Biochemistry Evaggelismos General Hospital, Athens, Greece
| | | | - Theodora Kapou
- Department of Oncology Evaggelismos General Hospital, Athens, Greece
| | | |
Collapse
|
23
|
Koumarianou A, Nikou G, Dimitroulopoulos D, Angelopoulos T, Papamichelakis M, Mandanas S, Chrisoulidou A, Vlachou E, Alexandrakis G, Papakostas P, Vaslamatzis M, Kaldrymidis P, Malachias A, Alevizopoulos N, Katsaounis P, Markussis V, Pazaitou K. Clinicopathologic considerations of neuroendocrine tumors (NETs) in Greece: A registry experience. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.e15191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - George Nikou
- Gastrenterology Department, Laiko University Hospital, Athens, Greece
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Vaslamatzis M, Laskarakis A, Argyrakos T, Alevizopoulos N, Zoublios C, Athanassiadi K. Clinicopathologic characteristics of patients (pts) with large-cell neuroendocrine carcinoma of the lung (LCNCL). J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.e19163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | - Th Argyrakos
- Department of Pathology Evaggelismos General Hospital, Athens, Greece
| | | | - Ch Zoublios
- Department of Oncology Evaggelismos General Hospital, Athens, Greece
| | | |
Collapse
|
25
|
Kapellos G, Alevizopoulos N, Polonyfi A, Ntziorva F, Laskarakis A, Vaslamatzis M, Mantzourani M. Survivin expression in non small lung cancer tissues. Preliminary results of a centre. Our experience. Lung Cancer 2012. [DOI: 10.1016/j.lungcan.2012.05.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
26
|
Vaslamatzis MM, Papaxoinis G, Karra P, Alevizopoulos N, Vamvouka C, Patila E, Ballis E, Testempassi E, Zoublios C, Ntouvelis E. Study of 19 patients (pts) with large-cell neuroendocrine tumors of the lung. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e18138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
27
|
Liapis K, Alevizopoulos N, Delimpasi S, Apostolidis J, Harhalakis N, Rontogianni D, Nikiforakis E. Alveolar rhabdomyosarcoma mimicking acute leukemia at presentation. J BUON 2009; 14:529-530. [PMID: 19810151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
|
28
|
Revelos K, Petraki C, Scorilas A, Stefanakis S, Malovrouvas D, Alevizopoulos N, Kanellis G, Halapas A, Koutsilieris M. Correlation of androgen receptor status, neuroendocrine differentiation and angiogenesis with time-to-biochemical failure after radical prostatectomy in clinically localized prostate cancer. Anticancer Res 2007; 27:3651-3660. [PMID: 17972531] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
UNLABELLED The aim of this study was to elucidate the prognostic value of the immunohistochemical detection of the androgen receptor (AR) status, the chromogranin A assessment of neuroendocrine differentiation (NED) and the CD34 assessment of microvessel density (MVD) with time-to-biochemical failure among surgically treated patients with clinically localized prostate cancer. PATIENTS AND METHODS Surgical specimens from 130 patients with clinically localized prostate cancer, treated with radical prostatectomy, were analyzed by immunohistochemistry on paraffin tissue sections. Full-length follow-up records were available for 94 patients. RESULTS Biochemical failure was observed in 37% of these patients. A statistically significant inverse relationship was observed between AR status and: (i) seminal vesicle invasion and (ii) surgical margin infiltration. Positive association was also detected between NED and: (i) Gleason's score, (ii) extracapsular extension, (iii) seminal vesicle invasion, (iv) surgical margin infiltration and (v) tumour volume. In addition, MVD was related to: (i) Gleason score, (ii) extracapsular extension, (iii) seminal vesicle invasion, (iv) pelvic lymph node metastasis and (v) tumour volume. Kaplan-Meier survival curves confirmed that Gleason score, extracapsular extension, seminal vesicle invasion, pelvic lymph node metastasis, tumour volume, NED, MVD and coexistence of increased NED and MVD may be potential biochemical failure predictors. However, in the multivariate analysis, MVD was the only independent prognostic factor for biochemical failure. CONCLUSION A high MVD index can estimate the risk for biochemical failure in clinically localized prostate cancer after radical prostatectomy.
Collapse
|
29
|
Petraki C, Vaslamatzis M, Petraki K, Revelos K, Alevizopoulos N, Papanastasiou P, Gregorakis A. Prostate cancer with small-cell morphology: an immunophenotypic subdivision. ACTA ACUST UNITED AC 2006; 39:455-63. [PMID: 16303720 DOI: 10.1080/00365590500199855] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
OBJECTIVE To study the immunophenotypic characteristics and clinical outcome of morphologically undifferentiated prostatic carcinoma with small-cell morphology (U-PC-SCM). MATERIAL AND METHODS Sixteen patients with U-PC-SCM were enrolled. The streptavidin-biotin complex immunohistochemical method was used on paraffin-embedded tissue sections to test positivity for prostate-specific antigen, prostate-specific acid phosphatase, CD57, androgen receptors, CK8-18, epithelial membrane antigen, carcinoembryonic antigen, CD56, neuron-specific enolase, chromogranin, synaptophysin, serotonin, various hormones, thyroid transcriptional factor-1 and Ki-67/MIB1. RESULTS Based on immunophenotypic criteria, we identified two groups of patients. The final diagnosis was U-PC (Gleason score 10) in Group 1 (n=9) and pure or mixed neuroendocrine small-cell carcinoma in Group 2 (n=7). Group 1 underwent total androgen blockade (TAB) with no major response and had a median survival of 9 months. In Group 2, three patients underwent TAB, two of whom died of progressive disease. The third patient showed a partial response (PR) for 18 months but eventually relapsed with liver metastatic lesions. He was then treated with cisplatin + etoposide and showed a PR for 3 months and survived for 5 months after the initiation of the second-line chemotherapy (CTH) treatment. The other four patients received six cycles of cisplatin + etoposide. There were two complete responses of >14 and >22 months, respectively and 2 PRs of 11 and 17 months, respectively, the partial responders surviving for 14 and 21 months, respectively. CONCLUSION U-PC-SCM with a neuroendocrine immunophenotype is a histogenetically distinct entity with different clinical and laboratory manifestations which responds well to a cisplatin + etoposide CTH regimen.
Collapse
|
30
|
Revelos K, Petraki CD, Vaslamatzis MM, Papanastassiou P, Mastoris C, Magkou C, Argyrakos T, Alevizopoulos N, Vrionis E, Koutsilieris M. The relation of androgen receptors status, neuroendocrine differentiation and angiogenesis to biochemical failure after radical prostatectomy for localized prostate cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4691] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | | | | | - C. Magkou
- Evangelismos Hospital, Athens, Greece
| | | | | | | | | |
Collapse
|